This Article Full Text (PDF) All Versions of this Article: 0897190008318913v1 21/6/402    most recent References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Saltiel, M. Search for Related Content Social Bookmarking                         What's this?

The Erythropoietic Receptors Agonists: FDA Warnings, Changing Guidelines, and Other Responses to Negative Data

Comprehensive Pharmacy Services, Costa Mesa, California, msaltiel{at}CPSpharm.net

In 2006, two large, international, randomized trials comparing high-intensity to low-intensity treatment with epoetin alfa were published. Both trials demonstrated that low-intensity treatment—with goal serum hemoglobin values of 11.3 or 10.5 to 11.5 g/dL, respectively—was associated with improved outcomes in patients with anemia and nondialysis-dependent chronic kidney disease. Over the following 6 to 12 months, regulatory agencies, insurers, and hospital systems would react, sometimes dramatically, as further literature became available that caused a rethinking of the appropriate use of these valuable agents. This article will summarize the response to recent literature regarding the administration of erythropoietic stimulating agents.

Key Words: Erythropoietic stimulating agonists • chronic kidney disease • anemia • regulatory controls

This version was published on December 1, 2008

Journal of Pharmacy Practice, Vol. 21, No. 6, 402-404 (2008)
DOI: 10.1177/0897190008318913


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?